Reducing Proteinuria in Diabetic CKD with ARBs

Introduction to ARB Selection

The American College of Cardiology recommends losartan and irbesartan as the first-line ARBs for reducing proteinuria and hard renal outcomes in diabetic patients with CKD, based on landmark trials (RENAAL and IDNT) 1, 2

The National Kidney Foundation suggests that losartan is the only ARB with FDA-approved indication specifically demonstrating reduction in hard renal endpoints in type 2 diabetic nephropathy, with benefits demonstrated in the RENAAL trial with 1,513 patients followed for mean 3.4 years 1, 2
The American Diabetes Association notes that irbesartan demonstrated similar renoprotective efficacy in the IDNT trial for type 2 diabetic nephropathy with macroalbuminuria 1, 2

The American Heart Association recommends starting with losartan 50 mg daily, titrate to 100 mg daily if tolerated and blood pressure goal not achieved, with a target blood pressure <130/80 mmHg 1, 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest considering adding an ACE inhibitor to losartan for dual RAS blockade if proteinuria remains elevated (ACR >500 mg/g) despite maximum losartan dose and blood pressure control 4, 5

The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) recommends monitoring serum creatinine, serum potassium, and blood pressure within 2-4 weeks of initiation or dose increase, and managing hyperkalemia with dietary restriction, volume correction, and potassium binders rather than stopping ARB 3
The International Society of Nephrology notes that combination with diuretics enhances efficacy, with 60-90% of patients in major trials using thiazide or loop diuretics with ARBs 1, 6